Expertise: Oncology & Hematology 96 results

Oncology & Hematology

The ADC Operations Playbook: Dose Strategy, Site Readiness, and Patient-Centric Execution

Antibody-drug conjugates (ADCs) are transforming oncology development—but they also bring significant operational complexity. Narrow therapeutic windows, payload-driven toxicities, biomarker-dependent enrollment, and evolving regulatory expectations demand a different approach than traditional oncology trials. This practical guide helps sponsors navigate ADC development...

Oncology & Hematology

Building Effective Long-Term Follow-Up Strategies in Advanced Therapies  

As cell and gene therapies continue to reshape treatment for complex and rare diseases, clinical research teams are navigating new operational realities. As these therapies advance, development strategies are also evolving to address new operational, regulatory, and evidence-generation challenges. Unlike many traditional therapies, cell and gene therapies may...

Oncology & Hematology

Operationalizing AI and RWE in Oncology: Converging Regulatory Landscapes

Artificial intelligence (AI) and real-world evidence (RWE) are playing a growing role across oncology development—from patient stratification and trial design to post-approval monitoring. As adoption accelerates, regulators are setting clearer expectations to ensure these tools are applied with transparency, rigor, and accountability. ...

Oncology & Hematology

Operationalizing ADC Clinical Trials: Dose, Safety, and Design

Antibody–drug conjugates (ADCs) are rapidly reshaping the oncology treatment landscape. By combining the targeting precision of monoclonal antibodies with the cytotoxic potency of small-molecule payloads, ADCs offer the promise of improved efficacy with more controlled toxicity. This potential has fueled...